Issue 79, 2021

Carboxyboranylamino ethanol: unprecedented discovery of boron agents for neutron capture therapy in cancer treatment

Abstract

Carboxyboranylamino ethanol (Me2N(BH2CO2H)CH2CH2OH, 1) was prepared in 75.0% yield by an amine-exchange reaction. Compound 1 shows lower cytotoxicity and higher anti-tumor efficacy in vitro towards the SCCVII cell line in comparison with 4-borono-L-phenylalanine (BPA) and methyl 2-hydroxyl-5-(1′-ortho-carbonylmethyl-1′,2′,3′-triazol-4′-yl)-benzonate (2). The bio-enhancement is interpreted using molecular docking calculations.

Graphical abstract: Carboxyboranylamino ethanol: unprecedented discovery of boron agents for neutron capture therapy in cancer treatment

Supplementary files

Article information

Article type
Communication
Submitted
07 ذو القعدة 1442
Accepted
01 صفر 1443
First published
03 صفر 1443

Chem. Commun., 2021,57, 10174-10177

Carboxyboranylamino ethanol: unprecedented discovery of boron agents for neutron capture therapy in cancer treatment

Y. Zhu, J. Cai, N. S. Hosmane, M. Suzuki, K. Uno, Y. Zhang and M. Takagaki, Chem. Commun., 2021, 57, 10174 DOI: 10.1039/D1CC03034E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements